載入中
AMEXHealthcareMedical - Devices
最新資料
US$2.46
+US$0.10 · +4.24%
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
前收盤價
US$2.46
+US$0.10 · +4.24%
盤前
US$2.49
+US$0.03 · +1.22%
10月8日 上午9:01 ET
盤中時間採用ET。市場資料可能有所延遲。
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
日內區間
目前US$2.46
52週區間
目前US$2.46
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
14
估值過高
情緒
48
多空交錯
風險
75
高風險
動能
34
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
日內區間
目前US$2.46
52週區間
目前US$2.46
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 145.4萬 USD | 143.4萬 USD | 541.5萬 USD | 1079.5萬 USD |
| 銷貨成本 | — | 230.6萬 USD | — | 304.8萬 USD | 617.9萬 USD |
| 毛利 | — | −85.2萬 USD | 143.4萬 USD | 236.7萬 USD | 461.6萬 USD |
| 研究與開發 | 8421.5萬 USD | 3933.2萬 USD | 2131.1萬 USD | 181.3萬 USD | 258.2萬 USD |
| 銷售、一般及管理費用 | 3023.3萬 USD | 2661.3萬 USD | 2106.4萬 USD | 935.2萬 USD | 942.5萬 USD |
| 營業費用 | 1.14億 USD | 6594.5萬 USD | 4237.5萬 USD | 1147萬 USD | 1200.7萬 USD |
| 利息收入 | 811.4萬 USD | 1051.5萬 USD | 93.4萬 USD | 112.2萬 USD | 11.9萬 USD |
| 利息支出 | 37.6萬 USD | 4.8萬 USD | 8.4萬 USD | — | — |
| 折舊和攤銷 | 325.1萬 USD | 230.6萬 USD | 98.6萬 USD | 32.4萬 USD | 24.8萬 USD |
| 營業利益 | −1.14億 USD | −6679.7萬 USD | −4094.1萬 USD | −910.3萬 USD | −739.1萬 USD |
| 淨利 | −1.03億 USD | −7927.9萬 USD | −4650.8萬 USD | −1076萬 USD | −727.2萬 USD |
公司資料更新於 2026年10月8日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$11.00
上漲空間 347.15%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1046.93萬0.00%2.3兆 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM633.14萬0.01%785.63億 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF312.38萬0.00%954億 USD0.05%US$233.49-1.56%
Vanguard Russell 2000 ETFVTWO187.17萬0.01%180億 USD0.06%US$112.21-1.26%
iShares Biotechnology ETFIBB160.84萬0.02%104.01億 USD0.44%US$203.34+0.12%
Dimensional - US Small Cap ETFDFAS141.26萬0.00%336.6億 USD0.31%US$77.92-1.38%
Schwab U.S. Small-Cap ETFSCHA107.41萬0.00%216.99億 USD0.03%US$32.61-1.47%
Vanguard Health Care ETFVHT88.74萬0.00%220億 USD0.09%US$315.31+0.78%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。